ARCHER II
59 evidence topics · 20 sources
Objective
Primary purpose: reduction of vision loss with monthly injections
Main and secondary objectives in the EU trial record
Confirmation of the phase 2 ARCHER findings
Vision protection at Months 15 and 24
Location and study date
Completion of enrollment in July 2025
Regions of the study sites and of enrolled participants
Expected timing of the Month 15 assessment and of study completion
Study design
Phase 3, randomized, double-masked, sham-controlled design
Randomization ratio and masking through Month 24
Masked and unmasked study roles
Study periods: screening, 24-month treatment, and Month 24 visit
Single protocol analyzed as two sub-studies for the United States filing
Original design announced in 2023: approximately 400 participants randomized 1:1 for 12 months
Second head-to-head phase 3 trial against pegcetacoplan no longer planned
Design informed by the phase 2 ARCHER trial
Open-label extension offered after Month 24
Eligibility criteria
Age, diagnosis, and study duration
Lesion size, multifocality, and junctional hyperautofluorescence on fundus autofluorescence
Best-corrected visual acuity of 45 to 83 letters
Reason for excluding eyes with baseline acuity below 45 letters
Fellow-eye choroidal neovascularization and fellow-eye GA treatment
Exclusion of study-eye choroidal neovascularization, prior intravitreal or AMD treatment, and uveitis
Exclusion for myopia, uncontrolled glaucoma, and prior ocular surgery in the study eye
Treatment
Vonaprument 5 mg monthly or sham monthly for 24 months
Study outcomes
Rationale for using confirmed best-corrected visual acuity loss of 15 or more ETDRS letters as the primary endpoint
Primary endpoints: confirmed loss of 15 or more letters through Month 15 and through Month 24
Month 24 dual primary endpoint added in August 2026
Landmark analysis and alpha split between Month 15 and Month 24
Timing of the primary analysis in earlier disclosures
Secondary endpoints: time to confirmed loss, low-luminance acuity, ellipsoid zone, and safety
FDA alignment on the endpoint without a lesion-growth requirement
Prior use of the endpoint in ophthalmology approvals
Functional primary endpoints of approved retinal products
| Indication and product | Functional primary endpoint |
|---|---|
| Wet AMD, Lucentis | “Trial 1 and 2: BCVA ≥15-letter change” |
| Wet AMD, Eylea and Eylea HD | “BCVA ≥15-letter change/Mean BCVA change” |
| Wet AMD, Vabysmo | “Mean BCVA change” |
| DME, Lucentis | “BCVA ≥15-letter change” |
| DME, Iluvien | “BCVA ≥15-letter change” |
| DME, Ozurdex | “BCVA ≥15-letter change” |
| GA | “No Approved Vision-Preserving Treatments” |
Clinical meaning of a loss of 15 or more letters
Frequency of loss of 15 or more letters in prior GA datasets
Approved GA therapies: anatomic endpoint without demonstrated visual benefit
“The approval of pegcetacoplan and avacincaptad was based on an anatomic endpoint of a reduction in the rate of GA expansion over time. However, functional data from two phase 3 clinical trials for each drug demonstrated no visual benefit to patients in the treatment groups.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Although change in visual acuity is often the primary endpoint in clinical trials for new retinal drug applications, approval of a drug based solely on anatomic outcomes is not unprecedented.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Basis in a prespecified analysis of the phase 2 ARCHER trial, whose primary endpoint was lesion growth
Enrichment of the ARCHER II population and expected event rate
Statistical analysis description
Number of participants (Planned and analyzed)
Enrollment of 659 participants
Statistical power and sub-study size
Number analyzed
No evidence found.
Description of analysis sets
Single study for the EU filing and two sub-studies of about 330 participants each for the United States filing
Sequence of the single-study and sub-study analyses
Definitions of efficacy and safety analysis populations
No evidence found.
Results
Participant disposition
Discontinuation below 10% and compliance above 95% as of August 2026
Disposition by treatment arm
No evidence found.
Baseline characteristics
Demographic and structural characteristics compared with ARCHER
| Characteristic | ARCHER (N = 270) | ARCHER II (N = 659) |
|---|---|---|
| Age, mean (SD) | “80.0 (8.2)” | “78.4 (8.0)” |
| Female | “61.5%” | “63.0%” |
| GA lesion size (mm2), mean (SD) | “7.36 (4.01)” | “7.23 (3.49)” |
| GA lesion location, subfoveal | “51.9%” | “54.8%” |
| Total EZ loss, mm2 (% of total area lost) | “12.7 (35.3%)” | “12.3 (34.3%)” |
Visual acuity characteristics compared with ARCHER
| Characteristic | ARCHER (N = 270) | ARCHER II (N = 659) |
|---|---|---|
| Mean BCVA (SD), letters | “58.4 (16.2)” | “65.8 (10.5)” |
| Baseline BCVA below 45 letters | “23.3%” | “0.0%” |
| Mean LLVA (SD), letters | “33.0 (16.9)” | “38.3 (17.2)” |
| Mean LLVD (SD), letters | “25.7 (16.9)” | “27.6 (15.6)” |
| LLVD below 30 letters | “62.4%” | “60.7%” |
Proportions with foveal lesions and with low-luminance deficit below 30 letters
Baseline characteristics by treatment arm
No evidence found.
Efficacy results
No evidence found.
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
No evidence found.
Study limitations
Summary: design features and absence of results
As of November 15, 2026, no efficacy or safety result of ARCHER II has been released; the sponsor expects the independent Data Monitoring Committee assessment of the Month 15 primary endpoint in the fourth quarter of 2026, sub-study results in the first quarter of 2027 if the endpoint is met, and study completion with the Month 24 analyses in the third quarter of 2027. The only disclosed trial-level data are pooled, masked baseline characteristics of 659 participants and sponsor statements on retention (90%), discontinuation (below 10%), and compliance (above 95%); baseline data by arm and the numbers analyzed have not been published.
The design has changed since it was first announced. In December 2023 the trial was planned with approximately 400 participants randomized 1:1 and a primary endpoint assessed through 12 months; the enrolled trial randomized 659 participants 2:1 to monthly vonaprument 5 mg or sham. The timing of the primary analysis was described as 12 to 18 months from dosing initiation in 2024, at least 12 months in July 2025, 12 to 15 months in December 2025, and Month 15 in 2026. A Month 24 dual primary endpoint was added in August 2026 while masked follow-up was ongoing, with alpha allocated between the two timepoints (the majority to Month 15); the sponsor's Form 10-Q states that there is no assurance regulators will accept the amended dual primary endpoint design.
For the U.S. filing, the single protocol is divided into two pre-defined sub-studies of about 330 participants each to address the FDA two-trial recommendation, so the replication rests on two subsets of one trial with a shared protocol and conduct. The sham comparator is an injection-free procedure, and the planned injection-controlled trial against pegcetacoplan (ARROW) was dropped in March 2025, so ARCHER II will provide no comparison with an approved GA therapy. The endpoint rationale rests on the phase 2 ARCHER trial, in which the 15-letter loss analysis was prespecified while the primary lesion-growth endpoint “did not reach statistical significance”. Eligibility excludes eyes with baseline BCVA below 45 letters, which the sponsor states was chosen because few such eyes had 15-letter loss events in ARCHER; results will therefore not describe eyes with lower baseline acuity. Patient-reported outcomes are listed as a secondary objective in the EU record, and no instrument has been named.